* Zura Bio Ltd ZURA.OQ ZURA.O is expected to report
results on
August 14 (estimated).
*
* Refinitiv's mean analyst estimate for Zura Bio Ltd is for
a
loss of 25 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Strong Buy".
* Wall Street's median 12-month price target for Zura Bio
Ltd is
$17, above its last closing price of $6.84.
This summary was machine generated August 12 at 02:02 GMT. All
figures in US dollars unless otherwise stated